A comprehensive review of medical therapy on benign prostatic hyperplasia

Sugianto, Ronald; Tirtayasa, Pande Made Wisnu; Duarsa, Gede Wirya Kusuma

doi:10.1016/j.sexol.2021.07.002

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…α1 adrenergic receptors have three subtypes: α1A, α1B, and α1D. 70% of human prostatic adrenoreceptors are made up of α1A which can reach 80% in BPE patients [ 2 ] .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement

Osman,

Elawady,

Fawaz

et al. 2024

Int Urol Nephrol

View full text Add to dashboard Cite

Purpose To compare the efficacy and the safety of Tamsulosin 0.4 mg/day and 0.8 mg/day in patients suffering from lower urinary tract symptoms due to benign prostatic obstruction. Patients and Methods A prospective interventional, double-blinded, controlled study was carried out on 93 patients who met the criteria and divided randomly into two groups: group A for Tamsulosin 0.4 mg/day and group B for Tamsulosin 0.8 mg/day. International prostate symptom score, post void residual urine volume, and maximum flow rate of urine were assessed before and after 4 weeks of treatment. Results Both study groups showed a significant reduction in storage sub-score but only frequency was significantly reduced in group B (P < 0.001). On the other hand, Tamsulosin 0.8 mg was superior to Tamsulosin 0.4 mg regarding voiding sub-score except for straining (P = 0.325). Accordingly, the total international prostate symptom score was significantly improved in group B versus group A (P < 0.001). Furthermore, maximum flow rate and post-void residual urine volume were notably improved in Group B as compared to Group A (P < 0.001). Of all adverse events only dizziness was noted to be statistically significant in Group B versus Group A (P < 0.001). Conclusion Tamsulosin 0.8 mg has shown better outcomes in treating patients who suffer from lower urinary tract symptoms due to benign prostatic enlargement than Tamsulosin 0.4 mg, and besides that, it is well tolerated. Trial registration number M S 292/2020, SID: 373, date: 22/4/2020.

show abstract

“…α1 adrenergic receptors have three subtypes: α1A, α1B, and α1D. 70% of human prostatic adrenoreceptors are made up of α1A which can reach 80% in BPE patients [ 2 ] .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement

Osman,

Elawady,

Fawaz

et al. 2024

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…Studies have reported varying degrees of symptom severity, response to standard pharmacotherapy, and progression to acute urinary retention or the need for surgical intervention among these individuals (15,16). This variability features the heterogeneity of BPH as a clinical entity and the multifactorial nature of its progression, which may be influenced by factors such as genetic predispositions, environmental exposures, and lifestyle choices (17).…”

Section: Introductionmentioning

confidence: 99%

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Mehmood,

Ayaz,

Kakakhel

2024

JHRR

View full text Add to dashboard Cite

Background: Benign prostate hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, prevalently impacts the aging male population, often disrupting the quality of life with its accompanying urinary symptoms. The intersection between BPH and prostatic inflammation has emerged as a focal point in urological research, with inflammation speculated to exacerbate BPH progression and symptoms. Understanding this relationship is pivotal in refining therapeutic approaches and improving patient outcomes. Objective: This study aimed to elucidate the effects of prostatic inflammation on the clinical outcomes of patients with BPH, focusing on symptom progression, treatment efficacy, and long-term complications. Methods: This Study Conducted at Gajju Khan Medical College Swabi, KPK, Pakistan, in the duration from January, 2023 to June, 2023. This prospective cohort study involved 126 men with BPH, categorized into two groups based on the presence (n=63) or absence (n=63) of prostatic inflammation. Data were collected over three years, with assessments including demographic information, clinical histories, and prostate examinations. Primary outcomes measured were the progression of BPH symptoms, urinary function, and prostate size. Secondary outcomes included quality of life, acute urinary retention, the need for surgical intervention, medication efficacy, and long-term complications. Statistical analyses employed included Chi-square tests, t-tests, and ANOVA, with SPSS software. Results: The group with prostatic inflammation showed significantly more severe symptom progression (p < 0.01), impaired urinary function (p < 0.01), and increased prostate size (p < 0.01) compared to the non-inflamed group. Secondary outcomes also favored the non-inflamed group with better quality of life scores (75.2 ± 5.2 vs. 78.8 ± 4.8, p < 0.01), lower rates of acute urinary retention (20.3% vs. 15.5%, p < 0.01). Conclusion: Prostatic inflammation significantly worsens the clinical outcomes of BPH, affecting symptom progression, treatment response, and the likelihood of long-term complications. These findings suggest the need for integrated therapeutic strategies that address both BPH and prostatic inflammation to optimize patient care.

show abstract

“…8 In addition, several studies prompt the advantages of combination treatment with α-blockers plus antimuscarinics in the improvement of patient quality of life (QoL) and remarkable reduction in bothersome storage symptoms. 9 Nevertheless, the extensive clinical potential of this combination, there is a difficult obstacle with its use due to the first-dose phenomenon (after the first dose is absorbed, a sudden and severe drop in blood pressure can occur, resulting in syncope (fainting)), 10,11 which explain the urgent need for simple, fast, and extremely sensitive analytical methods for quantification of TAM/SOL in biological fluids to help in diagnosis the fainting resulting from the first-dose phenomenon .…”

Section: Introductionmentioning

confidence: 99%

Innovative electrochemical electrode modified with Al₂O₃nanoparticle decorated MWCNTs for ultra-trace determination of tamsulosin and solifenacin in human plasma and urine samples and their pharmaceutical dosage form

et al. 2022

View full text Add to dashboard Cite

show abstract

A comprehensive review of medical therapy on benign prostatic hyperplasia

Cited by 4 publications

References 39 publications

Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement

Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Innovative electrochemical electrode modified with Al₂O₃nanoparticle decorated MWCNTs for ultra-trace determination of tamsulosin and solifenacin in human plasma and urine samples and their pharmaceutical dosage form

Contact Info

Product

Resources

About

A comprehensive review of medical therapy on benign prostatic hyperplasia

Cited by 4 publications

References 39 publications

Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement

Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement

Effects of Prostatic Inflammation on Clinical Outcomes in Patients with Benign Prostate Hyperplasia

Innovative electrochemical electrode modified with Al2O3nanoparticle decorated MWCNTs for ultra-trace determination of tamsulosin and solifenacin in human plasma and urine samples and their pharmaceutical dosage form

Contact Info

Product

Resources

About

Innovative electrochemical electrode modified with Al₂O₃nanoparticle decorated MWCNTs for ultra-trace determination of tamsulosin and solifenacin in human plasma and urine samples and their pharmaceutical dosage form